CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性 AML 的治疗——包括免疫治疗在内的新型治疗选择
英文原题：Treatment of Relapsed/Refractory AML-Novel Treatment Options Including Immunotherapy.
查看英文原题
Treatment of Relapsed/Refractory AML-Novel Treatment Options Including Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
急性髓系白血病是一种分子异质性疾病，由恶性髓系祖细胞的快速扩增和分化受损引起。总体而言，预后仍然较差，超过一半的患者在一线治疗后出现复发/难治性疾病。异基因造血干细胞移植（HCT）仍然是符合条件的患者获得治愈的最佳机会，而包括 BCL2、FLT3、IDH1/2 和 menin 抑制剂在内的新疗法的开发，这些疗法有效且通常更可耐受，使得能够更好地桥接至及时 HCT。尽管靶向治疗取得了早期成功，但仍需要更普遍和有效的治疗方法，目前正在研究众多靶向免疫治疗药物（包括 CAR-T、双特异性和三特异性抗体疗法）。
展开英文摘要原文
Acute myeloid leukemia is a molecularly heterogenous disease caused by the rapid expansion and impaired differentiation of malignant myeloid progenitors.
Overall, outcomes remain poor, and more than half of patients develop relapsed or refractory disease after front-line therapy. Allogeneic hematopoietic stem cell transplant (HCT) remains the best chance for cure for eligible patients, and the development of novel therapies including BCL2, FLT3, IDH1/2 and menin inhibitors, which are efficacious yet generally more tolerable, have enabled better bridging to prompt HCT.
Despite the early success of targeted therapies, more generalized and efficacious therapeutic approaches remain in need, and numerous targeted immunotherapeutic agents (including CAR-T, bispecific and trispecific antibody therapies) are currently under investigation.
论文信息
- 作者
- Moore CG、Stein A、Fathi AT、Pullarkat V
- 第一作者单位
- Massachussetts General Hospital, Boston, Massachussetts, USA.United States
- 通讯作者单位
- City of Hope National Medical Center, Duarte, California, USA.United States
- 文献类型
- 综述
- 期刊
- American journal of hematology2025 Mar
- 原文标识
- PubMed 39960017 · DOI 10.1002/ajh.27584